Detalhe da pesquisa
1.
Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
Antimicrob Agents Chemother
; 60(2): 757-65, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26574015
2.
Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
Antimicrob Agents Chemother
; 59(6): 3441-9, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25824231
3.
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Antimicrob Agents Chemother
; 57(6): 2654-63, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23529738
4.
Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.
Pediatr Infect Dis J
; 34(4): 398-405, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25599284
5.
In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Antiviral Res
; 93(2): 288-296, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22197635